Sign in Subscribe
Medical equipment industry

Breakthrough in Melanoma Detection: New Blood Test Holds Promise

Strategic Insights

— 1 min read

Researchers at the John Wayne Cancer Institute (JWCI) are making headlines with a new blood test that uses four genetic markers to detect melanoma cells in patients with no clinical signs of the disease. This innovative "reverse transcriptase polymerase chain reaction" (RT-PCR) assay, developed jointly with the National Genetics Institute, has shown promising results in detecting a single melanoma cell in over 10 million blood cells. The study, presented at the annual meeting of the American Society of Clinical Oncology (ASCO), has significant implications for early detection and treatment of this potentially deadly form of skin cancer.

Key Takeaways:

  • The new RT-PCR assay uses four genetic markers to detect melanoma cells in patients with no clinical signs of the disease.
  • The assay can identify a single melanoma cell in over 10 million blood cells, making it a highly sensitive tool for detecting disease.
  • Investigators at JWCI have used the assay to evaluate 119 melanoma patients, finding a significant correlation between the patient's stage/status of disease and the number of markers detected.
  • A higher number of melanoma markers in a patient's blood is associated with a poorer prognosis.
  • The JWCI team plans to use this technology to monitor a melanoma patient's response to surgery, immunotherapy, and chemotherapy.
  • The new assay has the potential to detect almost all types of melanoma cells, thanks to its design as an "umbrella" assay.

Statistics:

  • The new RT-PCR assay can detect a single melanoma cell in over 10 million blood cells.
  • 119 melanoma patients have been evaluated using the assay.
  • A higher number of melanoma markers in a patient's blood is associated with a poorer prognosis.
  • By the year 2000, an estimated one in 75 Americans will be affected by melanoma.
  • JWCI is a comprehensive cancer center known worldwide for its successful treatment of patients with solid cancer, particularly melanoma.

Sources:

  • /PRNewswire/
  • American Society of Clinical Oncology (ASCO)
  • John Wayne Cancer Institute (JWCI)
  • National Genetics Institute

Read more